Eledon Pharmaceuticals Inc

Healthcare · Biotechnology

2.50$ +2.3% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Eledon Pharmaceuticals Inc (ELDN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 126 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ELDN
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	37	30	26	27	23	21	26	23	20	17	13	18	15	11	14	11	193	197	192	184	177	171	161	155	150	93	82	107	96	126	81	120	115	177	161	145	130	169	147	126
Current Assets	36	30	26	25	21	19	24	21	17	14	10	15	12	10.0	13	9.8	115	116	110	103	96	88	79	73	68	60	49	74	63	56	48	87	82	144	128	111	96	136	114	93
Cash	19	23	24	22	19	17	23	19	16	13	9.1	14	11	8.8	12	8.8	114	114	109	101	94	85	77	70	66	56	46	41	3.7	4.6	5.7	26	6.8	21	8.5	5.7	3.7	23	6.2	6.8
Cash & Short-Term Investments	35	27	24	22	19	–	23	19	16	13	9.1	14	11	8.8	12	8.8	114	114	109	101	94	85	77	70	66	56	46	71	60	51	43	84	78	140	125	108	93	133	111	89
Receivables	–	–	–	–	–	–	–	–	–	0.6	0.7	0.7	1.0	0.2	0.2	0.2	0.2	0.1	0.2	0.1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.8	0.7	0.8	0.5	0.6	0.4
Inventory	–	–	–	–	–	–	–	–	–	0.1	0.5	0.7	0.5	0.9	0.8	0.8	0.4	1.3	-0.2	1.4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	–	–	–	0.3	0.3	0.2	0.2	0.1	0.1	0.3	0.2	0.8	0.7	0.6	0.8	–	–	0.6	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	0.0	–	–	44	49	49	49	49	49	49	49	49	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32
Total Liabilities	6.5	2.9	2.5	3.4	2.4	1.4	1.6	1.5	1.6	2.5	3.5	2.2	1.9	1.5	2.0	1.1	171	6.6	7.8	5.8	6.4	6.6	5.1	5.3	8.5	8.6	7.5	6.8	4.7	42	6.0	129	39	59	47	39	94	88	46	54
Current Liabilities	6.3	2.8	2.4	3.2	2.3	1.4	1.6	1.5	1.6	2.5	3.2	1.9	1.7	1.3	1.9	1.1	6.1	2.5	4.2	2.7	4.0	4.4	3.0	3.3	6.3	6.5	5.5	4.9	2.9	3.9	4.2	6.0	12	12	9.2	14	14	18	13	12
Short-Term Debt	0.0	3.4	–	–	–	–	–	–	–	–	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.2	0.2	0.4	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.4	0.4	0.4
Accounts Payable	0.9	0.3	0.3	0.4	0.2	–	0.4	0.7	0.8	0.7	0.5	0.8	0.3	0.3	0.7	0.2	0.8	1.4	1.5	0.9	1.6	1.8	1.0	1.3	3.9	2.2	2.9	2.2	0.5	1.0	1.9	2.1	5.9	5.8	2.9	5.8	4.6	3.6	6.6	3.2
Shareholders' Equity	30	27	23	23	21	–	24	22	18	14	9.9	16	13	9.5	12	9.4	22	191	184	179	171	164	156	149	141	84	75	100	91	83	75	-8.5	76	118	115	106	35	81	100	72
Retained Earnings	-166	-169	-173	-22	-25	-28	-30	-34	-37	-42	-46	-51	-53	-58	-66	-68	-74	-80	-89	-96	-106	-115	-125	-134	-144	-203	-214	-223	-234	-243	-253	-388	-311	-356	-362	-373	-391	-401	-440	-472
Shares Outstanding	0.0	0.1	0.0	4.2	6.9	0.4	7.7	9.4	9.4	9.4	9.4	12	13	13	17	17	20	15	15	15	15	14	14	14	14	14	14	24	30	24	30	42	55	60	77	77	77	75	112	114

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings